Pfizer RSV vaccine for infants has 'generally favorable' safety data, FDA staff say

The FDA is slated to make a decision on whether to approve Pfizer's shot in August, just before respiratory syncytial virus season in the fall.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.